MediXall (MDXL) Common Equity (2019 - 2024)
MediXall's Common Equity history spans 8 years, with the latest figure at -$3.6 million for Q3 2024.
- For Q3 2024, Common Equity rose 31.06% year-over-year to -$3.6 million; the TTM value through Sep 2024 reached -$3.6 million, up 31.06%, while the annual FY2023 figure was -$6.5 million, 77.78% down from the prior year.
- Common Equity reached -$3.6 million in Q3 2024 per MDXL's latest filing, up from -$7.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.0 million in Q1 2021 to a low of -$7.5 million in Q2 2024.
- Average Common Equity over 5 years is -$2.4 million, with a median of -$1.8 million recorded in 2022.
- Peak YoY movement for Common Equity: surged 1011.03% in 2021, then tumbled 3158.27% in 2022.
- A 5-year view of Common Equity shows it stood at $381904.0 in 2020, then crashed by 189.06% to -$340122.0 in 2021, then plummeted by 978.84% to -$3.7 million in 2022, then crashed by 77.78% to -$6.5 million in 2023, then surged by 44.53% to -$3.6 million in 2024.
- Per Business Quant, the three most recent readings for MDXL's Common Equity are -$3.6 million (Q3 2024), -$7.5 million (Q2 2024), and -$7.0 million (Q1 2024).